期刊文献+

两种剂量辛伐他汀治疗高脂血症的疗效及安全性的临床观察 被引量:3

The Efficacy and Safety of Two Dosages of Simvastatin in Patients with Hyperlipidemia
下载PDF
导出
摘要 目的:探讨辛伐他汀治疗高脂血症患者的疗效及安全性。方法:76例高脂血症患者,随机分为辛伐他汀20mg组(n=38)和40mg组(n=38),于晚睡前口服,治疗8周,监测血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、血清C反应蛋白(CRP)、肝肾功能、肌酸磷酸激酶,同时观察患者有无消化道症状、肌痛等不良反应。结果:两组血清TC、LDL-C、CRP浓度于治疗后均降低,与入院时比较均有统计学意义(P<0.01),两组间治疗后比较也有统计学意义(P<0.01)。结论:辛伐他汀对高脂血症患者的调脂有肯定的疗效,同时辛伐他汀强化降脂可有效调降血脂,且有良好的安全性及耐受性,无明显肝肾功能损害、肌溶解等不良反应。 Objective To investigate the efficacy and safety of simvastatin in patients with hyperlipidemia. Methods 76 patients with hyperlipidemia were randomized to the simvastatin 20 mg group(n=38)or simvastatin 40 mg group (n=38). All the patients took the drug orally before sleep for eight weeks. Serum TC, LDL-C, CRP, CK, liver function and renal function were measured before and after the treatment. The side effects such as myalgia and gastrointestinal symptom were also monitored. Results After treatment, serum ...
作者 倪子琴
机构地区 灌云县人民医院
出处 《实用医技杂志》 2008年第33期4727-4728,共2页 Journal of Practical Medical Techniques
关键词 辛伐他汀 高脂血症 疗效 安全性 Simvastatin Hyperlipidemia Efficacy Safety
  • 相关文献

参考文献2

二级参考文献22

  • 1Hopkins PN,Williams RR. A survey of 246 suggested coronary risk factors[J]. Atherosclerosis, 1981,40:1-52.
  • 2EUROASPIRE:a Europan Society of Cardiology survery of secondary prevention of coronary heart disease: principal results[J]. Eur Heart J, 1997,18:1569-1582.
  • 3Ross R. Atheroslerosis-an inflammatory disease[J]. N Engl J Med, 1999,340:115-126.
  • 4Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages:implications for atherosclerosis [ J]. Circulation, 2001,103 :1194-1197.
  • 5Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex,and hormone replacement treatment [J]. Circulation, 2000,101:1785-1791.
  • 6Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling[J]. Cir Res, 2001,89:1-2.
  • 7Yasojima K,Schwab C, McGeer EG, et al. Generation of C-Reactive protein and complement components in atheroscle-rotic plaques[J]. Am J Pathol,2001,158 : 1039-1051.
  • 8Tomai F,Crea F,Gaspardone A, et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasore-activity of the culprit lesion [J]. Circulation, 2001, 104 :1471-1476.
  • 9Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells[J].Circulation, 2000,102 : 2165-2168.
  • 10Nakajima T,Schulte S,Warrington K J, et al. T-cell-media-ted lysis of endothelial cells in acute coronary syndromes[J]. Circulation, 2002,105:570-575.

共引文献40

同被引文献49

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部